A standalone colon transplant is not performed in modern medicine. The colon can be transplanted, but only as part of a broader intestinal or multivisceral transplant, where it is included alongside the small bowel and sometimes other organs like the liver, stomach, and pancreas. The reason no one receives a colon-only graft comes down to a practical reality: people who lose their colon have good alternatives that do not require the extreme immunological risks of transplantation, while people who need an intestinal transplant typically need far more than just the colon.
Why No One Gets a Colon-Only Transplant
The colon’s primary jobs are absorbing water and electrolytes, fermenting fiber, and storing stool until it is ready to be passed. These are useful functions, but they are not life-sustaining in the way that the small intestine’s nutrient absorption is. When the colon is removed surgically, a procedure called a colectomy, the small intestine adapts to take over much of the water-absorption work. Animal research has shown this adaptation is substantial: in rat studies, water absorption in the ileum (the last section of the small intestine) increased significantly within two months of colectomy, and the absorptive surface area of the intestinal lining grew as well, with villus length increasing over 40%.
1Journal of Surgical Research. The effect of total colectomy on morphology and absorptive capacity of ileum in the ratA similar pattern has been documented in humans who undergo colectomy followed by an ileal pouch-anal anastomosis, commonly known as a J-pouch. The small intestine’s mucosal surface expanded substantially in both the jejunum and ileum, and total glucose and electrolyte absorption in the ileum increased in proportion to that surface area gain.
2PubMed. Morphological and functional adaptation of the small intestine after colectomy and ileal pouch-anal anastomosis in ratsBecause the body can compensate for a missing colon so effectively, there is no clinical scenario where a transplant team would subject a patient to lifelong immunosuppression just to replace it. The risk-benefit math simply does not work. Transplanting any part of the intestine carries uniquely severe immunological challenges compared to transplanting a kidney or liver, so surgeons reserve intestinal transplants for situations where there is no other option.
When the Colon Is Transplanted as Part of a Larger Graft
The colon does get transplanted, just never alone. In intestinal transplantation, surgeons may include the colon alongside the small bowel when they believe it will improve the patient’s fluid balance and reduce the frequency of loose stools. This was documented early in the field’s development: in a series of 16 small bowel transplants performed under tacrolimus-based immunosuppression, five grafts included the large bowel, and four of those patients retained their grafts with the colon intact.
3PubMed Central. Small intestinal transplantation in humans with or without the colonIncluding the colon is a judgment call that varies by center and by patient. Adding it can improve water absorption and give patients more formed stools, which matters for quality of life. But it also adds immunological complexity. One study found that omitting the colon from the graft was actually protective against graft-versus-host disease (GVHD) in children, significantly reducing the risk of that dangerous complication.
4PubMed Central. Graft Versus Host Disease After Intestinal Transplantation: A Single-center ExperienceThe decision to include the colon in a graft involves weighing the functional benefit against additional immune risk. In multivisceral transplants, where the stomach, pancreas, small bowel, and sometimes liver are all transplanted together, the colon may be included to create as complete a digestive system as possible. These are among the most complex operations in surgery.
Who Actually Needs an Intestinal Transplant
Intestinal transplantation is reserved for patients with intestinal failure, a condition where the small intestine cannot absorb enough nutrients to sustain life. Most of these patients depend on intravenous nutrition, called parenteral nutrition, delivered directly into the bloodstream through a central venous catheter. Parenteral nutrition can keep people alive for years, but it carries serious long-term risks: liver damage, bloodstream infections from the catheter, and progressive loss of venous access as veins become scarred or clotted.
The most common cause of intestinal failure in adults is short bowel syndrome, which occurs when large portions of the small intestine have been surgically removed due to conditions like mesenteric vascular disease, Crohn’s disease, or trauma. In children, the leading causes include necrotizing enterocolitis (a devastating bowel disease of premature infants), intestinal atresia (where the bowel fails to form properly before birth), and gastroschisis. Pediatric intestinal transplant outcomes may present particular challenges that differ from adult cases, and they are often analyzed separately in the research literature.
5PubMed Central. Pediatric Intestinal Transplantation: Analysis of the Intestinal Transplant RegistryBy contrast, the conditions that lead to colon removal, such as ulcerative colitis, familial polyposis, and colorectal cancer, do not cause intestinal failure. Removing the colon for these conditions is common, and the surgical alternatives work well enough that transplantation is unnecessary.
6PubMed. Metabolic consequences of total colectomyWhat Happens When the Colon Is Removed Instead
For conditions like severe ulcerative colitis or familial adenomatous polyposis, the standard surgical treatment is total proctocolectomy with ileal pouch-anal anastomosis, the J-pouch procedure. Surgeons remove the entire colon and rectum, fashion a reservoir from the end of the small intestine, and connect it to the anal canal. The result is that the patient can still pass stool through the normal route, without needing a permanent external bag.
Long-term outcomes for this procedure are reassuringly stable. In a cohort of 409 J-pouch patients followed for 15 years, functional outcomes held steady: patients averaged about six bowel movements during the day and two at night. Fecal continence was largely preserved, and quality-of-life scores remained excellent over the entire follow-up period. Ninety-one percent kept the same job at 15 years, and work, social activities, sports, travel, and sexual life all improved after surgery and stayed improved.
7PubMed Central. The Effect of Ageing on Function and Quality of Life in Ileal Pouch PatientsQuality-of-life measures also improved when comparing patients before and after the procedure. In a study that assessed patients both before their initial surgery and after their temporary ileostomy was reversed and the J-pouch was functioning, overall quality-of-life scores rose significantly.
8PubMed Central. Quality of life of ulcerative colitis patients treated surgically with proctocolectomy and J-pouch formationThat said, satisfaction is not universal. Patients who ended up with more than seven bowel movements per day, frequent nighttime episodes, or regular soiling tended to be less satisfied with the outcome. This was linked not only to the objective surgical result but also to psychological factors like stress tolerance.
9PubMed. Quality of life after total proctocolectomy and ileal J-pouch-anal anastomosisFor patients who are not candidates for a J-pouch, or who prefer not to have one, a permanent ileostomy is another well-established option. Stool drains into an external pouch worn on the abdomen. While the adjustment is significant, many people live full, active lives with an ileostomy. The colectomy itself carries a postoperative complication rate of roughly 28% for severe ulcerative colitis patients, with the most common issues being postoperative ileus and rectal stump leakage, though mortality is very low at around 0.5%.
10PubMed. Colectomy with ileostomy for severe ulcerative colitis-postoperative complications and risk factorsWhy Intestinal Transplants Are So Difficult
The intestine is the most immunologically active organ that surgeons transplant. It contains an enormous amount of lymphoid tissue and hosts a complex microbial community, both of which make rejection harder to control than in kidney or liver transplantation. The first clinical isolated intestinal transplant was performed in 1967, the first multivisceral transplant in 1983, and the first combined liver-intestinal transplant in 1990, but the field only became viable after the introduction of tacrolimus-based immunosuppression in the early 1990s.
11PubMed. History of clinical intestinal transplantationEven with modern drugs, intestinal transplant recipients face a gauntlet of complications. Acute rejection is common. Chronic rejection, when it develops, has no proven pharmacological treatment, and removing the graft is often the only option. Including the liver in the transplant appears to be protective against chronic rejection, which is one reason many centers perform combined liver-intestinal grafts.
12PubMed. Chronic Rejection After Intestinal Transplant: Where Are We in Order to Avert It?Graft-versus-host disease is another risk that is relatively unique to intestinal transplantation. Because the transplanted bowel carries so much donor immune tissue, the graft can attack the recipient’s body. In one center’s experience with 271 patients, 28 developed GVHD, typically presenting with a rash within about a month of surgery, and of those 28, more than half died, mostly from sepsis.
4PubMed Central. Graft Versus Host Disease After Intestinal Transplantation: A Single-center ExperiencePost-transplant lymphoproliferative disorder, a form of cancer driven by Epstein-Barr virus in immunosuppressed patients, is also a serious concern. Risk factors include the intensity of immunosuppression, younger age, and fewer tissue-type matches between donor and recipient.
13PubMed Central. Gastrointestinal manifestations, risk factors, and management in patients with post-transplant lymphoproliferative disorderIn pediatric intestinal transplant recipients, PTLD incidence has been reported as high as roughly 19% after isolated intestinal transplant in one center’s experience.
14PubMed. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantationThe Microbiome Factor
The gut microbiome adds another layer of complexity to intestinal transplantation. Researchers have found that shifts in microbial communities within the transplanted bowel can serve as an early warning signal of rejection. During episodes of acute rejection, populations of beneficial Firmicutes bacteria drop sharply while potentially harmful Proteobacteria surge. These shifts are pronounced enough that the relative proportions of certain bacterial groups in stool samples can discriminate between rejection and non-rejection states.
15PubMed Central. Characterization of the ileal microbiota in rejecting and nonrejecting recipients of small bowel transplantsThis is an active area of research, with some transplant teams exploring microbiome modulation as a strategy to support graft survival. The concept is distinct from fecal microbiota transplantation (FMT) for conditions like irritable bowel syndrome, where donor stool is introduced to reshape the recipient’s gut bacteria. In the transplant setting, the goal is to maintain a stable, healthy microbial community in the grafted bowel to prevent immune flare-ups.
16PubMed Central. Update on immunosuppressive strategies in intestinal transplantationDrugs That Help Patients Avoid Transplant Altogether
For patients with short bowel syndrome who depend on parenteral nutrition, a drug called teduglutide has changed the calculus of whether transplantation is necessary. Teduglutide is a synthetic version of a naturally occurring hormone that promotes growth of the intestinal lining, increasing its absorptive capacity. In a pivotal trial, about 63% of patients receiving teduglutide reduced their parenteral nutrition needs meaningfully, compared with 30% on placebo. The average reduction in intravenous fluid volume was roughly 4.4 liters per week.
17Gastroenterology. Teduglutide Reduces Need for Parenteral Support Among Patients With Short Bowel Syndrome With Intestinal FailureIn an earlier dose-finding study, three patients were completely weaned off parenteral nutrition entirely, including two who had been on it for more than five years.
18Gut. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndromeReal-world data in children tells a similar story. In a pediatric cohort, about two-thirds of patients experienced at least a 20% reduction in parenteral support volume, and 30% achieved full enteral autonomy, meaning they no longer needed intravenous nutrition at all.
19Intestinal Failure. Real-world efficacy of long-term teduglutide use in pediatric patients with short bowel syndromeBy reducing or eliminating the need for parenteral nutrition, teduglutide removes the primary reason many patients would eventually be referred for transplant. Fewer catheter-related infections, less liver damage from long-term intravenous feeding, and preserved venous access all reduce the urgency. For patients who still cannot get off parenteral nutrition despite teduglutide, transplantation remains the backstop.
Why Intestinal Grafts Are Hard to Preserve
One of the logistical barriers to intestinal transplantation is how quickly the organ deteriorates once it is removed from the donor. Among all abdominal organs, the intestine is the most vulnerable to damage from ischemia, the period when the organ is without blood flow during transport. Safe cold storage time is generally restricted to less than 10 hours, compared with much longer windows for kidneys and livers.
20PubMed. Organ-specific solutions and strategies for the intestinal preservationThe standard approach involves flushing the organ’s blood vessels with ice-cold preservation solution and storing it at 4°C, but even this causes metabolic disruption that can trigger injury when blood flow is restored after transplantation.
21PubMed. Progress in preservation of intestinal grafts by oxygenated hypothermic machine perfusionResearchers are exploring machine perfusion, a technique where the organ is continuously pumped with oxygenated, chilled fluid rather than simply sitting in a bag of cold solution. The idea is to keep the tissue metabolically active at a reduced rate, preventing the worst of the ischemic injury. This approach has shown promise for liver and kidney grafts and is now being investigated for the intestine as well.
The Cost and Access Question
Intestinal transplantation is one of the most expensive procedures in medicine. Data from a pediatric center in Singapore illustrates the scale: the average cost of the index hospitalization for intestinal transplant was equivalent to roughly US$166,000, and total costs in the first year after transplant averaged about US$376,000, driven largely by complications like PTLD and cytomegalovirus infection. Costs dropped steeply in subsequent years, falling to around US$127,000 in the second year and about US$41,000 by the third.
22PubMed Central. Healthcare cost of home parenteral nutrition and intestinal transplantation for paediatric chronic intestinal failure in SingaporeThese figures come from one center in one country and should not be generalized too broadly, but they illustrate a pattern that holds worldwide: the first year is enormously expensive, and costs decline as the patient stabilizes. Whether transplantation is more or less costly than indefinite parenteral nutrition depends on the individual case, since long-term parenteral nutrition also carries substantial ongoing costs for supplies, nursing care, and management of complications.
Tissue-Engineered Colon on the Horizon
The most futuristic answer to “can you get a colon transplant” may eventually come from regenerative medicine rather than from a donor organ. Researchers have been working on tissue-engineered colon, where scaffolds made from biodegradable polymers or decellularized tissue are seeded with intestinal stem cells to grow functional colonic tissue in the laboratory.
23Annals of Coloproctology. Tissue engineering and regenerative medicine approaches in colorectal surgeryIn animal experiments, this approach has produced tissue that looks remarkably like native colon. Engineered colon constructs grown from human progenitor cells in mice developed a columnar epithelium with the three main cell types of mature colon lining, along with smooth muscle, supporting connective tissue, and nerve cells.
24PubMed. Human tissue-engineered colon forms from postnatal progenitor cells: an in vivo murine modelEarlier work in rats demonstrated that tissue-engineered large intestine could recapitulate the architecture of native colon in striking detail, including properly structured crypts with goblet cells, a normal-appearing submucosa, smooth muscle layers, nerve plexuses in the correct positions, and normal blood vessel formation, all without signs of inflammation.
25Annals of Surgery. Tissue-Engineered Large Intestine Resembles Native Colon With Appropriate In Vitro Physiology and ArchitectureThis work is still preclinical, and the leap from growing small constructs in animal models to replacing a full human colon is enormous. Vascularization at human scale, integration with the recipient’s nervous system, and long-term durability are all unsolved problems. But the fact that laboratory-grown tissue can already mimic the colon’s layered architecture so faithfully suggests that the concept is not purely theoretical. If tissue-engineered colon ever reaches the clinic, it could sidestep the immunosuppression problem entirely, since the tissue could theoretically be grown from the patient’s own cells.